| Literature DB >> 25938011 |
Cecilia Cabello-Kindelan1, Shane Mackey1, Allison L Bayer2.
Abstract
There is a clear need to develop strategies to induce tolerance without the need of chronic immunosuppression in transplant recipient and in patients with autoimmunity. Adoptive T regulatory cell (Treg) therapy offers the potential of long-lasting protection. However, based on results of clinical trials so far with ex vivo expanded autologous Tregs in type 1 diabetic (T1D) patients, it seems unlikely that single immunotherapy with Treg infusion without immunomodulation regimens that promote stable donor Treg engraftment and persistence would afford truly significant clinical benefit. Combination therapies could provide improved outcomes with consideration of the fundamental factors required for Treg generation, homeostasis, and function to promote long-term donor Treg persistence to provoke beneficial therapeutic outcomes.Entities:
Keywords: IL-2; T regulatory cells; T-cells; tolerance; transplantation
Year: 2015 PMID: 25938011 PMCID: PMC4415881 DOI: 10.1007/s40472-015-0058-5
Source DB: PubMed Journal: Curr Transplant Rep